Drug Approval | July 02, 2022
Ascentage Pharma gets IND clearance by the US FDA for novel EED Inhibitor APG-5918
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
Tislelizumab is now approved in nine indications in China
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Innate to receive $5M milestone payment from AstraZeneca
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Tislelizumab is now approved for seven indications in China
Subscribe To Our Newsletter & Stay Updated
